Abstract: Objective:To investigate the feasibility of detection of serum pepsinogen (PG), gastrin-17 (G-17) and Helicobacter pylori antibody (anti-HP) in the gastric cancer screening, and to elucidate its clinical value. Methods:A total of 208 patients with early gastric cancer were selected as observation group; at the same time, 208 healthy examinees were regarded as blank control group. The levels of PGⅠ, PGⅡ and G-17 of the subjects in two groups were detected by enzyme-linked immunosorbent assay and latex-enhanced immunoturbidimetry; the positive rates of anti-HP were detected by ¹³C urea breath test; the serum levels of PG Ⅰ, PG Ⅱ and PG Ⅰ/PG Ⅱ ratio of the anti-HP positive subjects (anti-HP positive group) and anti-HP negative subjects (anti-HP negative group) were compared and analyzed. Results:Compared with blank control group, the serum PGⅠ/PGⅡ ratio and PGⅠ level of the subjects in observation group were significantly decreased(P<0.01), and the levels of PGⅡ,G-17and the positive rate of anti-HP were increased(P<0.01).Compared with anti-HP negative group, the serum PGⅠ/PGⅡ ratio and PGⅠ level of the subjects in anti-HP positive group were significantly decreased(P<0.01).The levels of PGⅡ and G-17 were significantly increased (P<0.01). Conclusion:The detection of positive rate of anti-HP combined with the ratio of PGⅠ/PGⅡ has important clinical significance in gastric cancer screening.The levels of G-17 and PG Ⅱ in the epithelial neoplasia lesion tissue can be used as indicators of gastric precancerous lesions.

Key words: gastrin-17, Helicobacter pylori antibody, stomach neoplasms, pepsinogen